Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed adenocarcinoma of the colon or rectum
• •* Locally recurrent or metastatic disease
• •Measurable disease, defined as ≥ 1 measurable lesion ≥ 20 mm by conventional CT scan OR ≥ 10 mm by spiral CT scan
• •* Bone metastases, ascites, and pleural effusion are not considered measurable disease
• •* Measurable lesions must be located outside a previously irradiated field
• •PATIENT CHARACTERISTICS:
• •Performance status
• •SWOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Bilirubin normal
• •No Gilbert's disease
• •Renal
• •Creatinine clearance \> 50 mL/min
• •Cardiovascular
• •No clinically significant cardiac disease that is not well controlled by medication, including any of the following conditions:
• •* Congestive heart failure
• •* Symptomatic coronary artery disease
• •* Cardiac arrhythmias
• •No myocardial infarction within the past year
• •Gastrointestinal
• •Must have a physically intact upper gastrointestinal tract
• •Able to swallow tablets
• •No history of peptic ulcer disease or gastroesophageal reflux
• •No malabsorption syndrome
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No known HIV positivity
• •No asthma, urticaria, or allergic-type reaction after prior treatment with aspirin or other nonsteroidal anti-inflammatory drugs
• •No other malignancy except curatively treated cancer with no evidence of active disease
• •No unresolved bacterial infection requiring antibiotics
• •No other serious infection
• •No known allergy to study drugs or sulfa drugs
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •No prior chemotherapy for colorectal cancer
• •* Patients relapsing \> 6 months after completion of prior adjuvant chemotherapy allowed
• •No other concurrent anticancer chemotherapy
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •See Disease Characteristics
• •At least 3 weeks since prior radiotherapy
• •No concurrent anticancer radiotherapy
• •Surgery
• •Recovered from prior surgery
• •No concurrent anticancer surgery
• •Other
• •Prior celecoxib for nonmalignant disorders allowed
• •No other concurrent cyclooxygenase-2 inhibitors or nonsteroidal anti-inflammatory drugs, including any of the following:
• •* Rofecoxib
• •* Ibuprofen
• •* Naproxen
• •* Etodolac
• •* Oxaprozin
• •* Diflunisal
• •* Nabumetone
• •* Tolmetin